Active Filter(s):
Details:
Fortrea will manage Incannex's IND opening Phase 2/3 clinical trial investigating IHL-42X which is a synergistic composition of dronabinol, a synthetic form of Tetrahydrocannabinol, and acetazolamide, a carbonic anhydrase inhibitor, for treatment of obstructive sleep apnoea.
Lead Product(s): Acetazolamide,Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: IHL-42X
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Incannex Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 18, 2023